Download click here - Broward Health

Record Research
Facility
1
BHCSPHYSICIAN
PRACTICE
Berkowitz, Richard. M.D.
Hip Reg
Zimmer Hip Registry: Multicenter Registry of All
Commercially Available Zimmer Hip Components.
open
Pharmacy
services
(regional/
onsite)
device
2
BHCSPHYSICIAN
PRACTICE
BHCSPHYSICIAN
PRACTICE
Berkowitz, Richard. M.D.
Knee Registry
Zimmer Knee Registry: Multicenter Registry of All
Commercially Available Zimmer Knee Components.
closed
none
Zimmer, Inc.
Rodriguez, Andres, M.D.
PDX-003-11
PDX-003-11: The Impact of Implementing a Universal
Newborn Screening for Critical Congenital Heart Disease.
open
none
Pediatrix Medical
4
BHM
Atanasoski-McCormick,
M.D.
Jostent
JOMED JOSTENT® CoronaryStent Graft Humanitarian
Device.
open
device
Abbott Laboratories
5
BHM
Ballard, Alicia, D.O.
PREP-Ballard
Ballard Skin Prep: Effects of Three Surgical Skin Preparation
Methods on the Visibility of Various Surgical Site Markings.
open
none
none
6
BHM
Barreras, Luis M.D.
CALGB 49802
Phase III Study of Adriamycin/Taxotere vs.
Adriamycin/Cytoxan in the Adjuvant Treatment of Node
Positive and High Risk Node Negative Breast Cancer.
closed
regional
ccop
7
BHM
Barreras, Luis M.D.
CALGB 59905
regional
ccop
8
BHM
Barreras, Luis M.D.
CALGB 9741
regional
ccop
9
BHM
Blanchard, Arnoux, M.D.
TIMI-52
A Randomized Phase III Trial of ABVD
closed
Versus Standford V± Radiation Therapy in Locally Extensive
and Advanced Stage Hodgkin’s Disease.
A Randomized Phase III Trial of Sequential Chemotherapy
closed
Using Doxorubin, Paclitaxel, and Cyclophosphamide or
Concurrent Doxorubicin and Cyclophosphamide Followed by
Paclitaxel at 14 to 21 Day Intervals in Women With Node
Positive Stage II/IIIA Breast Cancer.
A Clinical Outcomes Study of Darapladib versus
closed
Placebo in Subjects Following Acute Coronary Syndrome to
Compare the Incidence of Major Adverse Cardiovascular
Events (MACE). (Short title: The Stabilization of Plaques using
Darapladib-Thrombolysis In Myocardial Infarction 52 [SOLIDTIMI 52] Trial).
regional
GlaxoSmithKline
10
BHM
Blanchard, Arnoux, M.D.
TIMI-54
A Randomized, Double-Blind, Placebo Controlled, Parallel
closed
Group, Multinational Trial, to Assess the Prevention of
Thrombotic Events with Ticagrelor Compared to Placebo on a
Background of Acetyl Salicylic Acid (ASA) Therapy in
Patients with History of Myocardial infarction.
regional
AstraZeneca
3
Principal Investigator
PROIRB ID
BROWARD HEALTH CLINICAL TRIALS
Enrollment
open/closed
Sponsor
Zimmer, Inc.
11
BHM
Blanchard, Arnoux MD
12
BHM
Bray, Natasha DO
13
BHM
Carreira, Dominic M.
14
BHM
Carreira, Dominic M.
15
BHM
Carreira, Dominic M.
16
BHM
17
18
15693
Prospective, Randomized, Open-Label, parallel-Group, Active- open
Controlled, Multicenter Study Exploring the Efficacy, and
Safety of Once-Daily, Oral Rivaroxaban (BAY-59-7939)
Compared with that of Dose-Adjusted Oral Vitamin K
antagonists (VKA) for the Prevention of Cardiovascular
Events in Subjects with Nonvalvular Atrial Fibrillation
Scheduled for Cardioversion.
CV07012013open
CV07012013 Post Hospitializatio: A Pilot Quality of Life Study
BRAY
to Study Readmission Rates/Utilization of Cost and CoMorbidities of Post Hospitalization of Cardiac Patients When
Discharged for Follow-Up to a Hospital Out-Patient
Cardiology Clinic.
Carreira-Arthro Arthroscopic Reconstruction of the
yes
Acetabular Labrum using Allograft Fascia Lata: Technique and
Early Results.
Dynamometer Analysis of Hip Flexion Strength Recovery and open
Carreira-Dynomometer
Clinical Outcomes after an Endoscopic Iliopsoas Tendon
Release.
Carreira-HIPTRA HIPTRAC: The Relationships and Effects of Duration and
closed
Amount of Hip Traction on Nerve Injuries During Hip
Arthroscopy.
regional
pharmacuetical
Bayer
n/a
none
none
none
none
none
none
none
Catinella, Frank M.D
ANGINA RELIEF
open
none
Cardiogenesis
BHM
Czinn, Edwin A, M.D.
CL053
open
yes
Life Extension
BHM
Edelstein, Andrew, M.D.
CIS-USA
none
none
closed
open
device
Olympus Biotech
open
none
EM DEPT
open
none
Nova Southestern
TMR.1201.001-MAngina Relief Registry: A Multi-Center
Single Arm Observational Registry of the Cardiogenesis
Holmium: YAG Laser System Transmyocardial
Revascularization for Angina Reduction.
An Open Label, Pilot Study Utilizing and IV Infusion of
Propofol in Male and Female Volunteers with Refractory
Chronic Primary Insomnia.
CIS-USA-Cisapride Limited Access Program. Palliative Care
Protocol for Oral Cisapride Use.
19
BHM
Edelstein, Andrew, M.D.
H010002-Ellowitz
20
BHM
Ferber, Stephen
FerberDecisionMaking:
21
BHM
Faust, Jan Ph.D.
Urban Violence
H010002: OP-1 Implant is Indicated for the Use as an
Alternative to Autograph in Recalcitrant Bone Nonunions
Where Use of Autograph is Unfeasible and Alternative
Treatment have Failed. HDE
Medical Decision-Making and Risk: How Physician Behavior
and Attitude Correlate with the Framing
The Effects of Urban Violence and Accidental Injury on the
Presentation of Post-Traumatic Stress and Parental and
Familial Functioning.
22
BHM
Figueroa, Marga M.
PDX-001-11
Study Registry for Severe Retinopathy and Treatment on
Visual Outcomes of Premature Neonates.
23
BHM
Gellman, M.D., Joel
REDUCE-IT
24
BHM
Maini, Archana M.D.
20060359
25
BHM
Maini, Archana M.D.
26
BHM
27
none
Mednax Center
REDUCE-IT: A Multi-Center,Prospective, Randomized,
open
Double-Blind, Placebo-Controlled, Parallel-Group
Study to Evaluate the Effect of AMR101 on Cardiovascular
Health and Mortality in Hypertriglyceridemic Patients with
Cardiovascular Disease or at High Risk for Cardiovascular
Disease: REDUCE-IT (Reduction of Cardiovascular Events with
EPA - Intervention Trial).
SWOG 1201: A Randomized Phase II Pilot Study Prospectively open
Evaluating Treatment for Patients Based on ERCC1 (Excision
Repair Cross-Complementing 1) for Advanced/Metastatic
Esophageal, Gastric or Gastroesophageal Junction (GEJ)
Cancer.
regional
AMARIN
yes
ccop
20060359
A Randomized, Double-Blind, Placebo-Controlled, MultiCenter Phase 3 Study of Denosumab as Adjuvant
Treatment for Women with Early-Stage Breast Cancer at
High Risk of Recurrence (DCARE).
closed
regional
pharmacuetical
Amgen
Maini, Archana M.D.
CALGB70604
closed
none
ccop
BHM
Maini, Archana M.D.
E3108
A Randomized, Phase III Study of Standard Dosing versus
Longer Dosing Interval of Zoledronic Acid in Metastatic
Cancer.
A Phase II ProspectiveTrial Correlating Progression Free
Survival with CYP2D6 Activity in Patients with Metastatic
Breast Cancer Treated with Single Agent Tamoxifen.
open
none
ccop
28
BHM
Maini, Archana M.D.
E5202
A Randomized Phase III Study to Compare 5-FU, Leucovorin
and Oxaliplatin Versus 5-FU, Leucovorin,
Oxaliplatin and Bevacizumab in Patients with Stage II Colon
Cancer at High Risk for Recurrence to Determine
Prospectively the Prognostic Value of Molecular Markers.
closed
none
ccop
29
BHM
Maini, Archana M.D.
MAGRIT-BG
closed
regional
GlaxoSmithKline
30
BHM
Maini, Archana M.D.
N0147
N0147: A Randomized PhaseIII Trial of Oxaliplatin (OXAL)Plus closed
5-Fluorouracil (5-FU)/Leucovorin (CF) with or without
Cetuximab (C225) after Curative Resection for Patients with
Stage III Colon Cancer.
regional
ccop
MAGRIT 109493: A Double Blind, Randomized, PlaceboControlled Phase III Study To Assess The Efficacy Of
RecMAGE-A3 + AS15 Antigen-Specific Cancer
Immunotherapeutic As Adjuvant Therapy In Patients
With Resectable MAGE-A3-Positive Non-Small Cell Lung
Cancer.
open
A Phase III Open Randomized, Placebo-Controlled, Doubleclosed
Blind Study of Intravenous Calcium/Magnesium in Two
Different Versions to Prevent Oxaliplatin-Induced Sensory
Neurotoxicity.
Phase III Trial of Doxorubicin and Cyclophosphamide (AC)
closed
Followed by Weekly Paclitaxel With or Without Trastuzumab
as Adjuvant Treatment for Women with HER 2 Over
expressing or Amplified Node Positive or High-Risk Node
Negative Breast Cancer (an Intergroup Study.
regional
ccop
regional
ccop
NSABP B35
A Clinical Trial Comparing Anastrozole with
Tamoxifen in Postmenopausal Patients with Ductal
Carcinoma in Situ (DCIS) Undergoing Lumpectomy with
Radiation Therapy.
closed
regional
ccop
Maini, Archana M.D.
NSABP B38
regional
ccop
BHM
Maini, Archana M.D.
NSABP P-5
A Phase II ,Adjuvant Trial Comparing Three Chemotherapy
closed
Regimens in Women With Node-Positive Breast Cancer:
Docetaxel/Doxorubicin/Cycloph Osphamide (TAC): DoseDense (DD) Doxorubicin/Cyclophosphamine Followed by DD
Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus
Gemcitabine (DD AC->PG).
open
NSABP P-5: Statin Polyp Prevention Trial in Patients
with Resected Colon Cancer
regional
ccop
36
BHM
Maini, Archana M.D.
S0702-BG
S0702: A Prospective Observational Multicenter
Cohort Study To Assess the Incidence of Osteonecrosis of
the Jaw (ONJ) in Cancer Patients with Bone
Metastases Starting Zoledronic Acid Treatment.
open
none
ccop
37
BHM
Maini, Archana M.D.
S0927
A Randomized Placebo-Controlled Trial of Omega-3Fatty Acid for the Control of Aromatase Inhibitor-Induced
Musculoskeletal Pain and Stiffness In Women With Early
Stage Breast Cancer, Phase III.
closed
regional
ccop
38
BHM
Maini, Archana M.D.
Wyeth 3144A23004-
closed
regional
Wyeth
open
none
Biosense Webster, Inc.
open
radiology
Sorin Group
31
BHM
Maini, Archana M.D.
N08CB-BG
32
BHM
Maini, Archana M.D.
N9831
33
BHM
Maini, Archana M.D.
34
BHM
35
39
BHM
Osman, Ahmed M.D
Carto3
40
BHM
Osman, Ahmed M.D
IDE: RESPOND
Wyeth 3144A2-3004-WW: Randomized Double-Blind
Placebo-Controlled Trial of Neratinib (HKI-272) After
Trastuzumab in Women With Early-Stage HER-2/neu
Overexpressed/Amplified Breast Cancer.
Carto 3 System and Real Time Intracardiac Ultrasound for
Ablation of Drug Refractory Recurrent Symptomatic
Paroxysmal AF: Acute Procedural Outcomes Study.
Clinical Trial of the SonRtip Lead and Automatic AV-VV
Optimization Algorithm in the Paradym RF SonR CRT-D.
Protocol ITSY06. Version 4.0 dated 12/10/12.
41
BHM
Osman, Ahmed M.D
4SiteLead-Osman: The Longitudinal Surveillance Study of the 4-Site
Lead/Header System. CDM00048045.
open
none
42
BHM
Osman, Ahmed M.D
ISIS-ICD
ISIS-ICD: Protocol No. ITSY09: Inappropriate Shock
Reduction with PARAD+Rhythm Discrimination.
open
regional
Biosense Webster,
Inc.
Sorin Group
43
BHM
Osman, Ahmed M.D
STOP AF PA
STOP AF PAS: Sustained Treatment of Paroxysmal
Atrial Fibrillation Post-Approved Study.
open
regional
Medtronics
44
BHM
Perloff, David M.D.
BC22140 ROW
Cardiovascular Outcomes study to Evaluate the Potential of
Aleglitazar to Reduce Cardiovascular Risk in Patients with a
Recent Acute Coronary Syndrome (ACS) Event and Type 2
Diabetes Mellitus (T2D).
closed
regional
Hoffman-La Roc
45
BHM
Tranakas, Nicholas, M.D.
E3303
none
ccop
46
BHM
Vicuna, Ricardo MD
LCZ696B
closed
Phase II Study of C225 (Erbitux or Cetuximab) in Combination
With Cisplatin and Definitive Radiation in Unresectable Stage
IV Squamous Cell Carcinoma of the head and Neck.
LCZ696B: A Multicenter Randomized, Double-Blind,
open
Parallel Group, Active-Controlled Study to Evaluate
the Efficacy and Safety of LCZ696 Compared to
Enalapril on Morbidity and Mortality In Patients with
Chronic Heart Failure and Reduced Ejection Fraction.
regional
Novartis Pharma
47
BHM
Youngblut, JoAnne, Ph.D.
PICU/NICU
Death in the PICU/NICU: Parent & Family Functioning
closed
none
NIH
48
BHM
Youngblut, JoAnne, Ph.D.
PICU/NICU2
open
none
NIH
49
BHM.North
Lin, Ridwan M.D.
H020002-Li
PICU/NICU 2: Children's Responses to Sibling Death in
NICU/PICU in 3 Racial/Ethnic Groups. (Non-Hispanic Black;
Non-Hispanic White; Hispanic Latinos)
H020002: Neuroform Microdelivery Stent System.
Neuroform EZ Stent System (supplement).
open
device
Stryker Neurovas
50
BHM.North
Lin, Ridwan M.D.
H050001-Li
H050001: Wingspan Stent System with Gateway PTA Balloon open
Catheter.
device
Stryker Neurovas
51
BHM.North
Lin, Ridwan M.D.
H060001-Li
H060001: A007 Codman Enterprise Vascular
Reconstruction Device and Delivery System.
open
device
Codman and Sur
52
BHM.North
Urwin, Ross M.D., P
H020002-Ur
device
Stryker Neurovas
53
BHM.North
Urwin, Ross M.D., P
H050001-Ur
H020002: Neuroform Microdelivery Stent System, Neuroform open
EZ Stent System (supplement)
H050001: Wingspan Stent System with Gateway PTA Balloon open
Catheter.
device
Stryker Neurovas
54
BHM-PEDS
Rodriguez-Cortes, M.D.
AALL0232
AALL0232: High Risk B-Precursor Acute Lymphoblastic
Leukemia.
closed
regional
ccop
55
BHM-PEDS
Rodriguez-Cortes, M.D.
AALL0331
Standard Risk B- Precursor Accute Lymphoblastic Leukemia,
A Phase III Study.
closed
regional
ccop
56
BHM-PEDS
Rodriguez-Cortes, M.D.
AALL03B1
closed
regional
ccop
57
BHM-PEDS
Rodriguez-Cortes, M.D.
ABTR01B1
open
none
ccop
58
BHM-PEDS
Rodriguez-Cortes, M.D.
ACNS02B3
open
none
ccop
59
BHM-PEDS
Rodriguez-Cortes, M.D.
ACNS0331
A Phase III Double Randomized Trial. A Study Evaluating
closed
Limited Target Volume Boost Irradiation and Reduced Dose
Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in
Children with Newly Diagnosed Standard Risk
Medulloblastoma
A Phase III Study of Reduced Therapy in the Treatment of
closed
Children with Low and Intermediated Risk Extracranial Germ
Cell Tumors.
regional
ccop
60
BHM-PEDS
Rodriguez-Cortes, M.D.
AGCT0132
regional
ccop
61
BHM-PEDS
Rodriguez-Cortes, M.D.
AHOD0031
A Phase III Study of Dose-Intensive, Response-Based
closed
Chemotherapy and Radiation Therapy for Children
and Adolescents With NewlyDiagnosed Intermediate Risk
Hodgkin Disease.
Phase III Open Randomized Study of Chimeric-Antibody 14.18 open
(CH14.18) in High Risk Neuroblastoma Following
Myeloablative Therapy and Autologous Stem Cell Rescue.
regional
ccop
62
BHM-PEDS
Rodriguez-Cortes, M.D.
ANBLOO32
regional
ccop
63
BHM-PEDS
Rodriguez-Cortes, M.D.
ANBL00B1
Neuroblastoma Biology Studies. Biomarkers in Tumor Tissue open
Samples From Patients With Newly Diagnosed
Neuroblastoma or Ganglioneuroblastoma
regional
ccop
64
BHM-PEDS
Rodriguez-Cortes, M.D.
ARST0331
Vincristine, Dactinomycin, and Lower
Doses of Cyclophosphamide With or Without Radiation
Therapy For Patients With Newly Diagnosed Low-Risk
Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma.
closed
regional
ccop
65
BHM-PEDS
Rodriguez-Cortes, M.D.
D9902
open
none
ccop
66
BHM-PEDS
Rodriguez-Cortes, M.D.
POG9404
closed
on-site
ccop
67
BHM-PEDS
Rodriguez-Cortes, M.D.
POG9904
closed
regional
ccop
Classification of Acute Lymphoblastic Leukemia.
Children’s Oncology Group Protocol for Collecting and
Banking Pediatric Research Specimens Including Rare
Pediatric Tumors.
A Children’s Oncology Group Protocol for
Collecting and Banking Pediatric Brain Tumor
Research Specimens.
Group Wide Protocol for Collecting and
Banking Soft Tissue Sarcoma Specimens.
T-Cell #4 Protocol - Intensive Treatment for T-Cell Acute
Lymphoblastic Leukemia and Advanced
Stage Lymphoblastic Non-Hodgkin's Lymphoma
ALinC 17, Treatment for Patients with Low Risk Acute
Lymphoblastic Leukemia: A Phase III Study.
68
BHMPHYSICIAN
PRACTICE
Harris, Jonathan O M.D.
A9541004
Phase II Multicenter, Randomized, Double-Blind, Placebo
open
Controlled Study of the Safety and Efficacy of PF-03049423 In
Subjects with Ischemic Stroke.
on-site
pharmaceutical
Pfizer
69
BHMPHYSICIAN
PRACTICE
Harris, Jonathan O M.D.
NEST-3
NeuroThera Efficacy and Safety Trial: A Doubleblind,
Randomized, Shamcontrolled, Parallel Group,
Multicenter, Pivotal Study to Assess the Safety and
Efficacy of Transcranial Laser Therapy with the NeuroThera
Laser System for the Treatment of Acute
open
regional
Photo Thera, Inc.
70
BHMPHYSICIAN
PRACTICE
Landau, Evan MD
Head-Neck CA
open
none
21st Century Oncolgy
71
BHMPHYSICIAN
PRACTICE
Richmond, Gary M.D.
BL01
open
on-site
Abbott
Laboratories
72
BHMPHYSICIAN
PRACTICE
Shintre, Niranj, M.D.
HDE990014
open
device
Medtronics
73
BHMPHYSICIAN
PRACTICE
Shrock, Kevin B. M.D.
INTUIT
open
regional
Smith and Nephew
74
BHNorth
Faig, Douglas E. M.D.
NSABP B-49
open
yes
ccop
75
BHNorth
Faig, Douglas E. M.D.
CALBG 70305
A Randomized Study to Prevent Lymphedema In Women
Treated for Breast Cancer.
open
none
ccop
76
BHNorth
Faig, Douglas E. M.D.
S0702-North
open
none
ccop
77
BHNorth
Faig, Douglas E. M.D.
SWOG 0307
S0702: A Prospective Observational Multicenter
Cohort Study To Assess the Incidence of Osteonecrosis of
the Jaw (ONJ) in Cancer Patients with Bone
Metastases Starting Zoledronic Acid Treatment.
Phase III Trial of Bisphosphonates as Adjuvant Therapy for
Primary Breast Cancer.
closed
regional
ccop
A Prospectively Acquired Database of Head and Neck Cancer
Patients Receiving Radiation Therapy Using Modern
Techniques with a Quality of Life Assessment Tool within the
Broward Health Medical System as 21st Century Radiation
Oncology Offices and a Retrospective Head and Neck Cancer
Database Collection Study from 2011-2013.
A Randomized Double Blinded Controlled Trial of an Oral
Nurtitional Supplement Containing AN 777 in Older
Hospitalized Patients.
HDE990014: Enterra Therapy for the Treatment of Chronic,
Intractable Nausea and Vomiting Due to Gastroparesis.
INTUIT: Intramedullary Nailing for Treatment of Unstable
InterTrochs Outcome.
A Phase III Clinical Trial Comparing the Combination of
Docetaxel Plus Cyclophospamide to Anthracycline-Based
Chemotherapy Regimens for Women with Node-Positive or
High-Risk Node-negative, HER2-Negative Breast Cancer.
78
BHNorth
Faig, Douglas E. M.D.
E5103 NB
79
BHNorth
Faig, Douglas E. M.D.
S0715-NB
80
BHNorth
Faig, Douglas E. M.D.
E5508NB
81
BHNorth
Lieberfarb, Marshal, M.D.
RT1016-BHN
82
CDTC
Moscicki, Ann-Barba, Ph.D. HPV Infect
83
CDTC
Puga, Ana M.D.
84
CDTC
85
ECOG: 5103: A Double- Blind Phase III Trial of
Doxorubicin and Cyclophosphamide followed
by Paclitaxel with Bevacizumab or Placebo in
Patients with Lymph Node Positive and High Risk Lymph
Node Negative Breast Cancer.
S0715: "A Randomized Placebo-Controlled Trial of
Acetyl-L-Carnitine (ALC) For the Prevention of Taxane
Induced Neuropathy.
closed
regional
ccop
closed
regional
ccop
open
regional
ccop
open
regional
ccop
HPV Infections: Human Papillomavirus Infections in Children closed
and Adolescents.
none
UCSF Department
A5257
A Phase III Comparative Study of Three Non-Nucleoside
Reverse Transcriptase Inhibitor (NNRTI)-Sparing
Antiretroviral Regimens for Treatment-Naïve HIV-1 Infected
Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or
Darunavir with Emtricitabine/Tenofovir for
Naïve Treatment).
closed
on-site
NIH
Puga, Ana M.D.
A5279
Phase III Ultra-Short-Course Rifapentine/Isoniazid for the
Prevention of Active Tuberculosis in HIV-Infected
Individuals With Latent Tuberculosis Infection.
open
none
NIH
CDTC
Puga, Ana M.D.
open
on-site
NIH
86
CDTC
Puga, Ana M.D.
IMPAACT 1077HS IMPAACT 1077HS: HAART PROMISE Study. (Promoting
Maternal and Infant Survival Everywhere).
P1025
PACTG 1025: Perinatal Core Protocol, Version 4.0, dated
12/31/07.
open
none
NIH
87
CDTC
Puga, Ana M.D.
P1058A
open
on-site
NIH
88
CDTC
Puga, Ana M.D.
P1063
open
on-site
NIH
Randomized Phase III Study of Maintenance Therapy with
Bevacizumab, Pemetrexed, or a Combination of
Bevacizumab and Pemetrexed Following Carboplatin,
Paclitaxel and Bevacizumab for Advanced Non-Squamous
Phase III Trial of Radiotherapy Plus Cetuximab
Versus Chemoradiotherapy in HPV-Associated Oropharynx
Cancer.
Intensive pharmacokinetic Studies of New Classes of
Antiretroviral Drug Combinations in Children, Adolescents
and Young Adults.
IMPAACT P1063: Phase I/II Safety and Efficacy
Investigation of Atorvastatin for Treatment of Increased
LDL Cholesterol in HIVInfected Children and
Adolescents, and Young Adults.
P1066: A Phase I/II, Multicenter, Open-Label,
open
Noncomparative Study of the International Maternal,
Pediatric, Adolescent AIDS Clinical Trials (IMPAACT)
Group to Evaluate the Safety, Tolerability, Pharmacokinetics,
and Antiretroviral Activity of Raltegravir (Isentress, MK-0518)
IMPAACT P1074: A Prospective Surveillance
open
Study of Long-Term Outcomes In HIV-Infected
Infants, Children and Adolescents. Version 1.0
P1080: A Pilot Study of Psychiatric and Antiretroviral
closed
Medication Concentrations in HIV-1 Infected and Uninfected
Children and Adolescents. Version #1.0 dated 06/17/10.
89
CDTC
Puga, Ana M.D.
P1066
on-site
NIH
90
CDTC
Puga, Ana M.D.
P1074
none
NIH
91
CDTC
Puga, Ana M.D.
P1080
on-site
NIH
92
CDTC
Puga, Ana M.D.
P1085
Duration of Human Papilloma Virus Type-Specific
Antibody after Administration of Quadrivalent HPV Vaccine
to HIV-1 Infected Children Previously Enrolled in
IMPAACT P1047.
on-site
NIH
93
CDTC
Puga, Ana M.D.
P1090
Phase I/II, Open- Label Trial To Evaluate The Safety,
open
Tolerability, Pharmacokinetics and Antiviral Activity of
Etravirine (ETR) In Antiretroviral Treatment-Experienced HIV1 Infected Infants and Children, Aged >2 Months to <6 Years
and Antiretroviral Treatment-Naïve Infants Aged >2 Months
to <2 Years With/Without Exposure To Antiretrovirals As
Part of a PMTCT Regimen.
A Phase I/II, Multi-Center, Open-Label Pharmacokinetic,
open
Safety, Tolerability and Antiviral Activity of GSK1349572, A
Novel Integrase Inhibitor, in Combination Regimens in HIV- 1
Infected Infants, Children and Adolescents.
on-site
NIH
94
CDTC
Puga, Ana M.D.
P1093
on-site
NIH
95
CDTC
Puga, Ana M.D.
P1110
A Phase I Trial to Evaluate the Safety and
Pharmacokinetics of Raltegravir in HIV-1-Exposed
Neonates at High Risk of Acquiring HIV-1 Infection.
open
on-site
NIH
96
CDTC
Puga, Ana M.D.
PH201
open
none
NIH
97
CDTC
Puga, Ana M.D.
PH203
PH203: Pulmonary Complications in the Pediatric
HIV/AIDS Cohort Study. Adolescent Master Protocol.
(Pulmonary Complications in PHACS AMP (PCPA) Study.
open
none
NIH
98
CDTC
Puga, Ana M.D.
PHACS 200
Pediatric HIV/AIDS Cohort Study: AMP:
Adolescent Master Protocol.
open
none
NIH
99
CDTC
Puga, Ana M.D.
PHACS 202
open
none
NIH
PHACS PH201: "Memory Functioning in Children and
Adolescents with Perinatal HIV Infection".
Oral Health Among Participants in PHACS
PH200-Adolescent Master Protocol (AMP)
closed
100
CDTC
Puga, Ana M.D.
PHACS-Retention PHACS-Retention: Perspectives of HIV-Affected
Young Adults and Community Members of Technology and
Study Retention: A Formative Study for PHACS.
open
none
NIH
101
CDTC
Puga, Ana M.D.
SMARTT
open
none
NIH
102
CHS
Grigg, Rebecca, Ph.D.
MMP Project
open
none
CDC
103
CHS
Sension, Michael M.D.
A4001095
Randomized, Double-Blind, Comparative Trial of
closed
Maraviroc +Darunavir/Ritonavir Versus
Emtricitabine/Tenofovir +Darunavir/Ritonavir for the
Treatment of Antiretroviral-Naïve HIV-Infected Patients
With CCR5-Tropic HIV-1.
GS-US-216-0114: A Phase 3 Randomized, Double-Blind Study closed
to Evaluate the Safety and Efficacy of GS-9350-Boosted
Atazanavir Versus Ritonavir-Boosted Atazanavir Each
Administered with Emtricitabine/Tenofovir Disoproxil
Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve
Adults.
GS-US-236-0102: A Phase 3 Randomized, Double-Blind Study closed
to Evaluate the Safety and Efficacy of
Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS9350 Versus favirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve
Adults.
on-site
pharmaceutical
ViiV Healthcare
104
CHS
Sension, Michael M.D.
GS-US-216-0114
on-site
Gilead Science
105
CHS
Sension, Michael M.D.
GS236-0102
on-site
Gilead Science
106
CHS
Sension, Michael M.D.
GS-US-292-0112
A Phase 3, Open Label Safety Study of
open
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
Single-Tablet Regimen in HIV-1 Positive Patients with Mild
to Moderate Renal Impairment.
GS-US-236-0103: A Phase 3 Randomized, Double-Blind Study closed
to Evaluate the Safety and Efficacy of
Elvitegravir/Emtricitabine/Tenofovir
Disoproxil Fumarate/GS-9350 Versus Ritonavir- Boosted
Atazanavir Plus Emtricitabine/Tenofovir
Disoproxil Fumarate in HIV-1 Infected, Antiretroviral
Treatment-Naïve Adults.
GS-US-236-0118: A Phase 3 Open-label Safety Study of
closed
Cobicistat-containing Highly Active Antiretroviral Regimens
in HIV-1 Infected Patients with Mild to Moderate Renal
Impairment.
on-site
Gilead Science
107
CHS
Sension, Michael M.D.
GS236-0103
on-site
Gilead Science
108
CHS
Sension, Michael M.D.
GS236-0118
on-site
Gilead Science
Surveillance Monitoring for ART Toxicities
Study in HIV-Uninfected Children Born to HIV-Infected
Women. PHACS 100.
MMP: Medical Monitoring Project
109
CHS
Sension, Michael M.D.
GS259-0116
110
CHS
Sension, Michael M.D.
GS264-0110
111
CHS
Sension, Michael M.D.
GS-292-0109
112
CHS
Sension, Michael M.D.
GS292-0112
113
CHS
Sension, Michael M.D.
NG112574
114
CHS
Sension, Michael M.D.
ING114916-EAP
GS-US-259-0116: A Phase III, Double-Blind, Randomized,
Placebo-Controlled Study of the Effects of Ranolazine on
Major Adverse Cardiovascular Events in Subjects with a
History of Chronic Angina Who Undergo Percutaneous
Coronary Intervention with Incomplete Revascularization.
Sub-Study: Integrated Health Economics
GS-US-264-0110: A Phase 3B, Randomized, Open-label Study
to Evaluate the Safety and Efficacy of a Single Tablet Regimen
of Emtricitabine/Rilpivirene/Tenofovir Disoproxil Fumarate
Compared with a Single Tablet
Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate in HIV-1 Infected, antiretroviral Treatment-Naïve
Adults.
GS-US-292-0109: A Phase 3, Open-Label Study to Evaluate
Switching from a TDFContaining Combination Regimen to a
TAF-Containing Combination Single Tablet Regimen (STR) in
Virologically-Suppressed, HIV-1 Positive
Subjects.
GS-US-292-0112: A Phase 3, Open Label Safety Study of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
Single-Tablet Regimen in HIV-1 Positive Patients with Mild to
Moderate Renal Impairment.
ING112574: A Phase III Study to Demonstrate the Antiviral
Activity and Safety of Dolutegravir in HIV-1 Infected Adult
Subjects With Treatment Failure on an IntegraseInhibitor
Containing Regimen.
ING114916-EAP: Open Label Protocol for HIV infected, Adult
Patients with Integrase Resistance.
open
on-site
Gilead Science
closed
on-site
Gilead Science
open
on-site
Gilead Science
open
on-site
Gilead Science
open
on-site
GlaxoSmithKline
open
on-site
Viiv Healthcare
RecordsResearch
Facility
1 BHM
Principal Investigator
Berman, Barry M.D.
PROIRB ID
C-E2108 BG
2 BHM
Berman, Barry M.D.
C-NSABP-49
3 BHM
Landau, Evan MD
C-R0815
4 BHM
Lieberfarb, Marshal, M.D.
C-R0617 BG
5 BHM
Lieberfarb, Marshal, M.D.
C-RT1016
6 BHM
Maini, Archana M.D.
C-Z1041
Enrollment
open/closed
A Randomized Phase III Trial of the Value of
Early Local Therapy for the Intact Primary Tumor in
Patients with Metastatic Breast Cancer.
Phase III Clinical Trial Comparing the Combination of Docetaxel Plus
Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for
Women With Node-Positive or High-Risk Node-Negative, HER2-Negative
Breast Cancer.
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy
With or Without Short-Term Androgen Deprivation Therapy For Patients
With Intermediate- Risk Prostate Cancer.
open
Pharmacy services Sponsor
(regional/ onsite)
regional
ccop
open
regional
ccop
open
regional
ccop
A Randomized Phase III Comparison of Standard-Dose
(60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent
and Consolidation
Carboplatin/Paclitaxel +/- Cetuximab (IND#103444) In
Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.
closed
regional
ccop
closed
regional
ccop
open
regional
ccop
A Phase III Randomized Trial of Chemotherapy With or
open
Without Bevacizumab in Patients with Recurrent or
Metastatic Head and Neck Cancer.
Phase III Randomized Trial of Adjuvant Chemotherapy with or without
open
Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) - IIIA
Non-Small Cell Lung Cancer (NSCLC).
regional
ccop
regional
ccop
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of
closed
Carboplatin, Paclitaxel and BAY 43-9006 Versus Carboplatin, Paclitaxel and
Placebo in Patie nts with Unresectable Locally Advanced or Stage IV
Melanoma.
closed
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma:
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus
Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma.
ECOG: 5103: A Double- Blind Phase III Trial of
closed
Doxorubicin and Cyclophosphamide followed
by Paclitaxel with Bevacizumab or Placebo in
Patients with Lymph Node Positive and High Risk Lymph Node Negative
Breast Cancer.
Randomized Phase III Study of Maintenance Therapy with Bevacizumab,
open
Pemetrexed, or a Combination of
Bevacizumab and Pemetrexed Following Carboplatin,
Paclitaxel and Bevacizumab for Advanced Non-Squamous.
GOG 0262: A Randomized Phase III Trial of
closed
Every-3-Weeks Paclitaxel Versus Dose Dense Weekly
Paclitaxel in Combination with Carboplatin with or without Concurrent and
Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of
Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube
Cancer.
regional
ccop
regional
ccop
regional
ccop
regional
ccop
regional
ccop
NATIONAL CANCER INSTITUTE CENTRAL IRB SERVICES
Phase III Trial of Radiotherapy Plus Cetuximab
Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer.
Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75
Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of
Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in
Patients with HER-2 Positive Operable Breast Cancer.
7 BHM
Maini, Archana M.D.
C-E1305
8 BHM
Maini, Archana M.D.
C-E1505
9 BHM
Maini, Archana M.D.
C-E2603
10 BHM
Maini, Archana M.D.
C-E2805
11 BHM
Maini, Archana M.D.
C-E5103 BG
12 BHM
Maini, Archana M.D.
C-E5508BG
13 BHM
Maini, Archana M.D.
C-GOG 0262
14 BHM
Maini, Archana M.D.
C-NSABP 36
15 BHM
Maini, Archana M.D.
C-NSABP 40
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, closed
Epirubicin and
Cyclophosphamide (Fec) to Four Cycles of Adriamycin and
Cyclophosphamide (Ac), With or Without Celecoxib, in Patients with NodeNegative Breast Cancer.
regional
ccop
closed
regional
ccop
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast closed
Cancer.
CIRB: TAILORx: (PACCT-1) Trial Assigning Individualized
closed
Options for Treatment.
A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC- 75 closed
Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of
Aclitaxel Plus Trastuzumab Followed by FEC-75 Plus
Trastuzumab in Patients with HER-2 Positive Operable
Breast Cancer.
regional
ccop
regional
ccop
regional
ccop
Intensive Treatment for Intermediate
open
Risk Relapse of Childhood BPrecursor
Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine
Strategies.
Intensified Open Methotrexate, Nelarabine
open
(Compound 506U78 IND# 52611) and Augmented BFM Therapy for Children
and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic
Leukemia.
regional
ccop
regional
ccop
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with
Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic
Complete Response (pCR) of Adding Capecitabine or Gemcitabine to
Docetaxel when Administered Before AC with or without Bevacizumab and
Correlative Science Studies Attempting to Identify Predictors of High
Likelihood for pCR with Each of the Regimens.
16 BHM
Maini, Archana M.D.
C-SWOG 0307
17 BHM
Maini, Archana M.D.
C-PACCT-1 BG
18 BHM
Maini, Archana M.D.
C-Z1041 BHM
19 BHM
Rodriguez-Cortes, H M.D.
C-AALL0433
20 BHM
Rodriguez-Cortes, H M.D.
C-AALL0434
21 BHM
Rodriguez-Cortes, H M.D.
C-AALL05B1
A Children’s Oncology Group Protocol for Collecting and Banking Relapsed open
Acute Lymphoblastic Leukemia Research Specimens.
regional
ccop
22 BHM
Rodriguez-Cortes, H M.D.
C-AALL07P1
open
regional
ccop
23 BHM
Rodriguez-Cortes, H M.D.
C-AALL08B1
open
regional
ccop
24 BHM
Rodriguez-Cortes, H M.D.
C-AALL0932
A Phase II Pilot Trial of Bortezomib (PS341, Velcade, IND#58,443) in Combination with Intensive Re-Induction
Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL)
and Lymphoblastic Lymphoma (LL).
Classification of Newly Diagnosed Acute
Lymphoblastic Leukemia
Treatment of Patients with Newly
Diagnosed Standard Risk BPrecursor
Acute Lymphoblastic Leukemia
open
regional
ccop
25 BHM
Rodriguez-Cortes, H M.D.
C-AAML0431
closed
regional
ccop
26 BHM
Rodriguez-Cortes, H M.D.
C-AAML0531
Treatment of Down Syndrome Children with Acute Myeloid Leukemia
(AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years.
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg)
Combined with Conventional chemotherapy for De Novo Acute Myeloid
Leukemia (AML) in Children, Adolescents, and Young Adults.
closed
regional
ccop
27 BHM
Rodriguez-Cortes, H M.D.
C-AAML1031
A Phase III Randomized Trial for Patients
with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and
Sorafenib (BAY 43-9006, IND#69896, NSC# 724772)
open
regional
ccop
28 BHM
Rodriguez-Cortes, H M.D.
C-ACCL0933
29 BHM
Rodriguez-Cortes, H M.D.
C-ACCRN07
A Randomized Open-Label Trial of Caspofungin versus Fluconazole to
Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy
for Acute Myeloid Leukemia (AML): A Groupwide Phase III Study.
open
regional
ccop
open
none
ccop
open
regional
ccop
open
regional
ccop
A Children's Oncology Group Study for Collecting and
open
Banking Ewing Sarcoma Specimens.
A Pilot Study of Chemotherapy Intensification by adding Vincristine,
open
Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with
an Interval Compression Schedule in Newly Diagnosed Patients
with Localized Ewing Sarcoma Family of Tumors.
none
ccop
none
ccop
Phase III Randomized Trial of Adding
Vincristine-Topotecan-Cyclophosphamide to
Standard Chemotherapy in Initial Treatment of NonMetastatic Ewing Sarcoma.
Treatment of Children with All Stages of
Hepatoblastoma.
A Phase III Children and Adolescents with
Newly Diagnosed Low-Risk Hodgkin Disease.
open
regional
ccop
open
none
ccop
closed
none
ccop
Protocol for the Enrollment on the Official
COG Registry, The Childhood Cancer Registry Research Network (CCRN)
30 BHM
Rodriguez-Cortes, H M.D.
C-ACNS0334
Phase III Randomized Trial for the Treatment of Newly Diagnosed
Supratentorial PNET and High Risk
Medulloblastoma in Children < 36 months Old with Intensive Induction
Chemotherapy with Methotrexate Followed by Consolidation with Stem
Cell Rescue vs. the Same Therapy Without Methotrexate".
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients
with Newly Diagnosed Ependymoma Ages 1 to 21 Years: A
Groupwide Phase III Study.
31 BHM
Rodriguez-Cortes, H M.D.
C-ACNS0831
32 BHM
Rodriguez-Cortes, H M.D.
C-AEWS07B1
33 BHM
Rodriguez-Cortes, H M.D.
C-AEWS07P1
34 BHM
Rodriguez-Cortes, H M.D.
C-AEWS1031
35 BHM
Rodriguez-Cortes, H M.D.
C-AHEP0731
36 BHM
Rodriguez-Cortes, H M.D.
C-AHOD0431
37 BHM
Rodriguez-Cortes, H M.D.
C-AHOD04B1
AHOD04B1: Hodgkin Disease (HD) Banking Study.
open
none
ccop
38 BHM
Rodriguez-Cortes, H M.D.
C-ALTE05N1
Umbrella Long-Term Follow-Up Protocol.
open
none
ccop
none
ccop
39 BHM
Rodriguez-Cortes, H M.D.
C-ANBL00P3
A Phase III Randomized Trial Of Intravenous Gammaglobulin therapy For open
Patients With
Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Sydrome Treated
With Chemotherapy and
Prednisone.
40 BHM
Rodriguez-Cortes, H M.D.
C-AOST6B1
open
none
ccop
41 BHM
Rodriguez-Cortes, H M.D.
open
none
ccop
42 BHM
Rodriguez-Cortes, H M.D.
C-AREN0321
C-AREN03B2
A Children's Oncology Group Protocol for Banking and
Osteosarcoma Specimens.
Treatment of High Risk Renal Tumors.
Renal Tumors Classification, Biology, and Banking Study.
open
none
ccop
43 BHM
Rodriguez-Cortes, H M.D.
C-AREN0532
open
none
ccop
44 BHM
Rodriguez-Cortes, H M.D.
C-AREN0533
Treatment for Very Low, and Standard Risk
Favorable Histology Wilms Tumor.
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms
Tumors: A Groupwide Phase III Study.
open
none
ccop
45 BHM
Rodriguez-Cortes, H M.D.
C-AREN0534
Treatment for Patients with Bilateral, Multicentric, or BilaterallyPredisposed Unilateral Wilms Tumor: A Groupwide Phase III Study.
open
regional
ccop
46 BHM
Rodriguez-Cortes, H M.D.
C-ARST0332
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas
(NRSTS) in Patients Under 30 Years of Age.
closed
regional
ccop
47 BHM
Rodriguez-Cortes, H M.D.
ARTST08P1
open
regional
ccop
open
Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell
Lung Cancer.
Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5closed
FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the
Combination of Bevacizumab and Cetuximab for Patients
with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.
Randomized Phase III Trial of Oxaliplatin
closed
(OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without
Cetuximab (C225) after Curative Resection for Patients with Stage III Colon
Cancer.
regional
ccop
regional
ccop
regional
ccop
A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant
Folfox Plus Celecoxib Or Placebo For Patients With
Resected Stage III Colon Cancer.
TAILORx: (PACCT-1) Trial Assigning Individualized
Options for Treatment.
open
regional
ccop
closed
regional
ccop
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab
[IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460])
in Combination with Intensive Multi-Agent Interval Compressed Therapy
for Patients with
High-Risk
Rabdomyosarcoma:
A Groupwide Pilot Study.
Randomized
Phase
III Double
Blind Trial Evaluating
48 BHNorth
Faig, Douglas E. M.D.
CALGB 30801
49 BHNorth
Faig, Douglas E. M.D.
CALGB 80405
50 BHNorth
Faig, Douglas E. M.D.
C-N0147NB
51 BHNorth
Faig, Douglas E. M.D.
C-SWOG C80702
52 BHNorth
Faig, Douglas E. M.D.
C-PACCT-1 BHN
53 BHNorth
Lieberfarb, Marshal, M.D.
C-N107C
N107C: A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS)
open
Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic
Brain Disease.
regional
ccop
54 BHNorth
Lieberfarb, Marshal, M.D.
C-R0924
Androgen Deprivation Therapy and High
open
Dose Radiotherapy With or Without Whole-Pelvic
Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate
Cancer: A Phase III Randomized Trial.
regional
ccop
Record Research
Facility
1 BHM
Principal Investigator
PROIRB ID
Broward IRB Monitored Exempt Research
Sponsor
Bray, Natasha D.O.
E-Bray 4296
A Retrospective Observational
Analysis Showing the Prevalence of Mycobacterium
Tuberculosis Coinfection with Pneumocystis Jiroveci
Pneumonia at Broward Health Medical Center.
GME
2 BHM
Bray, Natasha D.O.
E-NASAL CANNULA
A Retrospective Analysis of the Use of Humidified
GME
High Flow Nasal Cannula Oxygen Therapy at Broward
General Medical Center.
3 BHM
Cross, Brian D.O.
E-Tibia Frac
Percutaneous Plating of Pediatric Tibia Fractures.
Trauma Services
4 BHM
El Sanadi, Nabil M.D.
E: ANGIO.072013
Pre-hospital Management of Acute ACE-Inhibitor
Induced Angioedema. Case Report.
Emergency Department
5 BHM
El Sanadi, Nabil M.D.
E-Bath Salts
Emergency Department
6 BHM
Emanuel, Laverne A, R.N.
E-Neonat
7 CDTC
Garvie, Patricia Ph.D.
E-ATN 071
Characteristics of Synthetic Cathinone ("Bath Salts")
and Synthetics Cannabinoid ("Spice")
Neonatal Encephalopathy Registry. Vermont Oxford
Network.
ATN 071: Neurocognitive Assessment in Youth
Initiating HAART.
8 BHM
Hyzy, Mathew D.O.
E HYZY
NONE
9 BHM
Lin, Ridwan M.D.
E-RSDOS
Treatment Rehabilitation of Periprosthetic
Supracondylar Femur Fractures with the
Megaprosthesis. Retrospective Chart Review.
Retrospective Stroke Data Outcome Study (RSDOS).
10 BHM
Lopez, Edwin
E-CENSUS-NHAMC
U.S. Census
11 BHM
Carreira, Dominic M.D.
OBERD
12 BHM
Stump, Christina M
E-STUMP
13 BHM
Vanegas, Katalin
E-VANEGAS
14 BHM
Habib, Fahim M.D., MPH
FACS
Rush, Joel D.O.
E-Habib
Census Bureau: National Hospital Ambulatory
Medical Care Survey (NHAMCS).
OBERD: Outcome Based Electronic Research Database
General Data Collection Project.
Protocol: Implementing a Delirium Screening Protocol
Program in ICU.
Evaluating an Evidence Based Protocol and a Urinary
Catheter Reminder to Remove Unnecessary Urinary
Catheter.
A Comprehensive Retrospective Assessment of the
Factors that Influence Outcome Following Injury.
15 BHM
E-Infect Rates
Pediatrix
NIH/CDTC
BH Stroke Program
BHM Orthopaedics
Barry University
Barry University
GME
GME
Retrospective Chart Review of Infection Rates in
Patients Requiring Internal Fixation of Tibia Fractures
and Fasciotomies for Acute Compartment Syndrome.